Adherence to antihypertensive treatment during the COVID-19 pandemic: findings from a cross-sectional study

Abstract Background Nonadherence to antihypertensive treatment is one of the main causes of the lack of blood pressure (BP) control. The coronavirus disease (COVID-19) pandemic imposes substantial social restriction impairing the medical care routine, which may influence adherence to the antihyperte...

Full description

Bibliographic Details
Main Authors: Mayra Cristina da Luz Pádua Guimarães, Juliana Chaves Coelho, Juliano dos Santos, Camila Braga de Oliveira Higa, Carime Farah Flórido, Renata Jae Won Lee, Grazielli Soares Paes, Giovanio Vieira da Silva, Luciano Ferreira Drager, Angela Maria Geraldo Pierin
Format: Article
Language:English
Published: BMC 2022-12-01
Series:Clinical Hypertension
Subjects:
Online Access:https://doi.org/10.1186/s40885-022-00219-0
_version_ 1811190440330788864
author Mayra Cristina da Luz Pádua Guimarães
Juliana Chaves Coelho
Juliano dos Santos
Camila Braga de Oliveira Higa
Carime Farah Flórido
Renata Jae Won Lee
Grazielli Soares Paes
Giovanio Vieira da Silva
Luciano Ferreira Drager
Angela Maria Geraldo Pierin
author_facet Mayra Cristina da Luz Pádua Guimarães
Juliana Chaves Coelho
Juliano dos Santos
Camila Braga de Oliveira Higa
Carime Farah Flórido
Renata Jae Won Lee
Grazielli Soares Paes
Giovanio Vieira da Silva
Luciano Ferreira Drager
Angela Maria Geraldo Pierin
author_sort Mayra Cristina da Luz Pádua Guimarães
collection DOAJ
description Abstract Background Nonadherence to antihypertensive treatment is one of the main causes of the lack of blood pressure (BP) control. The coronavirus disease (COVID-19) pandemic imposes substantial social restriction impairing the medical care routine, which may influence adherence to the antihypertensive treatment. To assess the rate of nonadherence to antihypertensive drug treatment during the COVID-19 pandemic. Methods This is a cross-sectional study evaluating hypertensive adult patients from a tertiary outpatient clinic. From March to August 2020, patients were interviewed by telephone during the social distancing period of the COVID-19 pandemic. We evaluated biosocial data, habits, attitudes, and treatment adherence using the 4-item Morisky Green Levine Scale during the social distancing. Uncontrolled BP was defined by BP ≥ 140/90 mmHg. Clinical and prescription variables for drug treatment were obtained from the electronic medical record. We performed a multivariate analysis to determine the predictors of nonadherence to BP treatment. Results We studied 281 patients (age 66 ± 14 years, 60.5% white, 62.3% women, mean education of 9.0 ± 4 years of study). We found that 41.3% of the individuals reported poor adherence to antihypertensive drug treatment and 48.4% had uncontrolled BP. Subsample data identified that adherence was worse during the pandemic than in the previous period. The variables that were independently associated with the nonadherence during the pandemic period were black skin color (odds ratio [OR], 2.62; 95% confidence interval [CI], 1.46–4.68), and intermittent lack of access to antihypertensive medication during the pandemic (OR, 2.56; 95% CI, 1.11–5.89). Conclusions Beyond traditional variables associated with poor adherence, the lack of availability of antihypertensive medications during the study underscore the potential role of pandemic on hypertension burden.
first_indexed 2024-04-11T14:51:14Z
format Article
id doaj.art-f4e4a7ccb54f4d1ba8fed57d2c07283c
institution Directory Open Access Journal
issn 2056-5909
language English
last_indexed 2024-04-11T14:51:14Z
publishDate 2022-12-01
publisher BMC
record_format Article
series Clinical Hypertension
spelling doaj.art-f4e4a7ccb54f4d1ba8fed57d2c07283c2022-12-22T04:17:28ZengBMCClinical Hypertension2056-59092022-12-0128111010.1186/s40885-022-00219-0Adherence to antihypertensive treatment during the COVID-19 pandemic: findings from a cross-sectional studyMayra Cristina da Luz Pádua Guimarães0Juliana Chaves Coelho1Juliano dos Santos2Camila Braga de Oliveira Higa3Carime Farah Flórido4Renata Jae Won Lee5Grazielli Soares Paes6Giovanio Vieira da Silva7Luciano Ferreira Drager8Angela Maria Geraldo Pierin9University of São Paulo Nursing SchoolUniversity of São Paulo Nursing SchoolUniversity of São Paulo Nursing SchoolUniversity of São Paulo Nursing SchoolUniversity of São Paulo Nursing SchoolUniversity of São Paulo Nursing SchoolUniversity of São Paulo Nursing SchoolUniversity of São Paulo Medical SchoolUniversity of São Paulo Medical SchoolUniversity of São Paulo Nursing SchoolAbstract Background Nonadherence to antihypertensive treatment is one of the main causes of the lack of blood pressure (BP) control. The coronavirus disease (COVID-19) pandemic imposes substantial social restriction impairing the medical care routine, which may influence adherence to the antihypertensive treatment. To assess the rate of nonadherence to antihypertensive drug treatment during the COVID-19 pandemic. Methods This is a cross-sectional study evaluating hypertensive adult patients from a tertiary outpatient clinic. From March to August 2020, patients were interviewed by telephone during the social distancing period of the COVID-19 pandemic. We evaluated biosocial data, habits, attitudes, and treatment adherence using the 4-item Morisky Green Levine Scale during the social distancing. Uncontrolled BP was defined by BP ≥ 140/90 mmHg. Clinical and prescription variables for drug treatment were obtained from the electronic medical record. We performed a multivariate analysis to determine the predictors of nonadherence to BP treatment. Results We studied 281 patients (age 66 ± 14 years, 60.5% white, 62.3% women, mean education of 9.0 ± 4 years of study). We found that 41.3% of the individuals reported poor adherence to antihypertensive drug treatment and 48.4% had uncontrolled BP. Subsample data identified that adherence was worse during the pandemic than in the previous period. The variables that were independently associated with the nonadherence during the pandemic period were black skin color (odds ratio [OR], 2.62; 95% confidence interval [CI], 1.46–4.68), and intermittent lack of access to antihypertensive medication during the pandemic (OR, 2.56; 95% CI, 1.11–5.89). Conclusions Beyond traditional variables associated with poor adherence, the lack of availability of antihypertensive medications during the study underscore the potential role of pandemic on hypertension burden.https://doi.org/10.1186/s40885-022-00219-0HypertensionAdherenceCOVID-19Drug treatment
spellingShingle Mayra Cristina da Luz Pádua Guimarães
Juliana Chaves Coelho
Juliano dos Santos
Camila Braga de Oliveira Higa
Carime Farah Flórido
Renata Jae Won Lee
Grazielli Soares Paes
Giovanio Vieira da Silva
Luciano Ferreira Drager
Angela Maria Geraldo Pierin
Adherence to antihypertensive treatment during the COVID-19 pandemic: findings from a cross-sectional study
Clinical Hypertension
Hypertension
Adherence
COVID-19
Drug treatment
title Adherence to antihypertensive treatment during the COVID-19 pandemic: findings from a cross-sectional study
title_full Adherence to antihypertensive treatment during the COVID-19 pandemic: findings from a cross-sectional study
title_fullStr Adherence to antihypertensive treatment during the COVID-19 pandemic: findings from a cross-sectional study
title_full_unstemmed Adherence to antihypertensive treatment during the COVID-19 pandemic: findings from a cross-sectional study
title_short Adherence to antihypertensive treatment during the COVID-19 pandemic: findings from a cross-sectional study
title_sort adherence to antihypertensive treatment during the covid 19 pandemic findings from a cross sectional study
topic Hypertension
Adherence
COVID-19
Drug treatment
url https://doi.org/10.1186/s40885-022-00219-0
work_keys_str_mv AT mayracristinadaluzpaduaguimaraes adherencetoantihypertensivetreatmentduringthecovid19pandemicfindingsfromacrosssectionalstudy
AT julianachavescoelho adherencetoantihypertensivetreatmentduringthecovid19pandemicfindingsfromacrosssectionalstudy
AT julianodossantos adherencetoantihypertensivetreatmentduringthecovid19pandemicfindingsfromacrosssectionalstudy
AT camilabragadeoliveirahiga adherencetoantihypertensivetreatmentduringthecovid19pandemicfindingsfromacrosssectionalstudy
AT carimefarahflorido adherencetoantihypertensivetreatmentduringthecovid19pandemicfindingsfromacrosssectionalstudy
AT renatajaewonlee adherencetoantihypertensivetreatmentduringthecovid19pandemicfindingsfromacrosssectionalstudy
AT graziellisoarespaes adherencetoantihypertensivetreatmentduringthecovid19pandemicfindingsfromacrosssectionalstudy
AT giovaniovieiradasilva adherencetoantihypertensivetreatmentduringthecovid19pandemicfindingsfromacrosssectionalstudy
AT lucianoferreiradrager adherencetoantihypertensivetreatmentduringthecovid19pandemicfindingsfromacrosssectionalstudy
AT angelamariageraldopierin adherencetoantihypertensivetreatmentduringthecovid19pandemicfindingsfromacrosssectionalstudy